Overview of Ibuprofeno GP

Property	Description
Active Ingredient	Ibuprofen
Pharmacological Class	Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common Use	Symptomatic relief of pain, fever, and inflammation
Form	Tablets, Capsules, Oral Suspension/Syrup
Origin	Synthetic Compound (Propionic acid derivative)

Ibuprofeno GP: What Type of Medicine is It?

Ibuprofeno GP is a nonsteroidal anti-inflammatory drug (NSAID) whose therapeutic action is derived entirely from its single active ingredient, Ibuprofen. This medicinal product is formally classified within the pharmacological class of non-narcotic analgesics and is a key representative of the propionic acid derivative chemical group, known chemically as isobutylpropanoic acid. The identity of Ibuprofeno GP is based on this established compound, which is a synthetic compound manufactured to provide reliable relief. Its status as an effective analgesic is clinically recognized worldwide, confirming the drug's role as a foundational agent for managing acute discomfort.

What is the Composition and Form of Ibuprofeno GP?

The core composition of Ibuprofeno GP is the single active ingredient, Ibuprofen, combined with an inert pharmaceutical vehicle to create the final product. As a single-ingredient product, its focus is on delivering the one therapeutic compound. The drug is commonly supplied as an oral preparation, including various dosage forms such as tablets, soft capsules, and flavored oral suspensions or syrups. This versatility in form ensures the oral route of administration is accessible, for instance, in a liquid suspension for children or individuals who cannot swallow solids.

What is the General Purpose of Ibuprofeno GP?

The general purpose of Ibuprofeno GP is to alleviate discomfort by simultaneously addressing the body’s fundamental responses to stimuli: pain, fever, and inflammation. Its classification as an NSAID grants it a triple functional profile, acting as an analgesic (pain-reliever), an antipyretic (fever-reducer), and an anti-inflammatory agent. Ibuprofen is utilized for reducing fever and managing mild to moderate pain. This action works by temporarily inhibiting the substances in the body that signal these responses, which makes the drug a valuable tool for providing symptomatic relief.

Regulatory References

Ibuprofen - StatPearls - NCBI Bookshelf

What side effects are possible with Ibuprofeno GP?

Possible side effects and safety information

Ibuprofeno GP, containing the NSAID Ibuprofen, is associated with documented safety risks as defined in official regulatory labeling. These safety characteristics are classified by the specific body system affected and may demonstrate an increased risk based on the duration of use or the dosage administered.

Official government warnings highlight the risk of serious cardiovascular thrombotic events, which includes both myocardial infarction (heart attack) and stroke. This risk may increase with longer duration of use and appears greater with higher doses of the medication. Additionally, the use of all NSAIDs carries an increased risk of serious gastrointestinal adverse events, including gastrointestinal bleeding, ulceration, and perforation, which can be fatal and can occur without warning symptoms. The risk of these complications is higher in the older adult population and with increasing NSAID dose.

Officially Documented Adverse Reactions by System-Organ Class

Adverse reactions documented in official prescribing information span several systems.

Gastrointestinal Disorders: Common effects include dyspepsia, heartburn, nausea, vomiting, and abdominal pain.
Nervous System Disorders: Effects may include headache, dizziness, and tinnitus (ringing in the ears).
Vascular Disorders: Fluid retention and the onset or worsening of hypertension have been reported.
Renal and Urinary Disorders: Serious effects include the possibility of renal failure, particularly in at-risk patients.

Hypersensitivity and Severe Skin Reactions

The medicine is associated with various hypersensitivity reactions, including the very rarely observed anaphylactic shock. Furthermore, Severe Cutaneous Adverse Reactions (SCARs)—including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)—have been reported, which are life-threatening. Regulatory information indicates that patients appear to be at the highest risk of these serious skin reactions early in the course of therapy.

Specific Safety Constraints

The use of Ibuprofen is contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery and should not be used in individuals with a history of recurrent peptic ulcer/haemorrhage. Its use is also contraindicated in the third trimester of pregnancy due to fetal risk. NSAIDs also have the potential to mask symptoms of infection.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented information regarding ibuprofen overdose, strictly based on authoritative government regulatory sources. It is not intended as medical advice but as a summary of the official product profile.

Documented Overdose Manifestations

Symptoms following an overdose of ibuprofen typically involve the gastrointestinal and central nervous systems. Initial signs may include nausea, vomiting, abdominal pain, drowsiness, dizziness, and lethargy. Less common, but documented, signs include tinnitus (ringing in the ears) and hypotension (low blood pressure).

Serious and Life-Threatening Outcomes

Severe toxicity is associated with major complications affecting the central nervous system and kidneys. The most serious outcomes officially documented include seizures, coma, acute renal failure, and severe metabolic acidosis. These manifestations can occur with high exposures and require immediate medical attention.

Emergency Action and Management

No specific antidote for ibuprofen overdose exists. Treatment is symptomatic and supportive, focusing on managing the patient's condition and correcting fluid, electrolyte, and acid-base imbalances. Gastric decontamination, such as administering activated charcoal, may be performed by healthcare professionals within the first hour post-ingestion, if appropriate.

When to Seek Immediate Medical Help:

If an overdose is suspected, contact a Poison Control Center or seek emergency medical help right away. This action is mandatory regardless of the presence of severe symptoms, as clinical signs may be delayed for several hours after ingestion. Specific populations, such as children and those with pre-existing renal impairment, may be at higher risk for severe toxicity.

Therapeutic Uses of Ibuprofeno GP

Ibuprofeno GP is relevant across therapeutic domains involving heightened symptomatic responses, providing support where additional management of discomfort is needed. This medication is commonly used to help with symptoms related to fever and for managing pain or addressing symptoms related to inflammatory states caused by many conditions. Its use helps ease the overall symptom burden and supports general well-being during symptomatic phases.

Pain, Inflammation, and Fever Management

Ibuprofeno GP is applicable within clinical settings that involve acute or disruptive symptom patterns. Common clinical scenarios of use include seeking relief for tension headaches, dental discomfort, and general muscular aches. It is also applied in situations involving recurrent manifestations, such as the pain of primary dysmenorrhea (menstrual cramps), and for discomfort associated with arthritis and minor injuries.

“The medication is commonly used for managing symptoms that interfere with daily comfort and create noticeable physiological strain.”

This use contributes to easing discomfort during periods of heightened symptoms and may assist with supporting daily comfort and routine.

Quick Fact Block

Quick Fact: Relief for Key Symptoms
Symptom Domain	Common Scenario
Pain & Inflammation	Musculoskeletal aches, sprains/strains, arthritis
Fever & Systemic Discomfort	Flu-like symptoms, elevated body temperature
Cyclical Pain	Primary dysmenorrhea (menstrual cramps)

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Ibuprofeno GP?

This section defines the populations eligible and non-eligible to use Ibuprofeno GP, based strictly on official governmental regulatory labeling.

Eligibility by Population Status

Status	Population/Condition
Contraindicated	Individuals with a known allergy to Ibuprofen or other NSAIDs (like aspirin) [Source: Regulatory Labeling].
Contraindicated	Patients with severe heart failure (NYHA Class IV), severe renal failure, or severe hepatic failure [Source: Regulatory Labeling].
Contraindicated	Patients with active or previous recurrent peptic ulceration/haemorrhage [Source: Regulatory Labeling].
Contraindicated	Use is prohibited during the last trimester of pregnancy [Source: Regulatory Labeling].
Restricted Use	Elderly patients (60 years) must use the lowest effective dose for the shortest possible duration [Source: Regulatory Labeling].
Restricted Use	Patients with mild-to-moderate renal or hepatic function reduction [Source: Regulatory Labeling].
Age Rules	Adults and adolescents (12 years) are generally eligible for standard formulations; minimum age for pediatric forms is 6 months [Source: Regulatory Labeling].

Official Eligibility Summary

Regulatory documents establish absolute contraindications for individuals with hypersensitivity or severe organ system dysfunction. Use is also strictly prohibited for treating peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. For conditions like mild hypertension or moderate organ impairment, regulations mandate restricted use and caution to manage inherent risks, ensuring the medication is only administered within an officially established risk profile.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Ibuprofeno GP, as a non-steroidal anti-inflammatory drug (NSAID), has documented interactions with several categories of medicinal products. Concomitant use with other NSAIDs, including cyclooxygenase-2 inhibitors, should be avoided due to the increased risk of gastrointestinal adverse effects. Combining this medicine with low-dose acetylsalicylic acid (aspirin) for anti-platelet effect is not generally recommended, as ibuprofen may reduce its cardio-protective effect, especially with regular long-term use.

Clinically Significant Interactions

The effects of anticoagulants (e.g., warfarin) may be enhanced, increasing the risk of bleeding; close monitoring of blood parameters is necessary. Ibuprofeno GP can reduce the therapeutic effects of diuretics, ACE inhibitors, and angiotensin II antagonists, and the combination carries an increased risk of kidney function impairment, particularly in elderly patients. Plasma concentrations of lithium and methotrexate may be increased due to reduced renal clearance, potentially leading to toxicity. The risk of gastrointestinal ulceration or bleeding is also increased when taken with oral corticosteroids, anti-platelet agents, or Selective Serotonin Re-uptake Inhibitors (SSRIs). Always consult a healthcare professional regarding concurrent use with any other medicine or product, including alcohol.

Mechanism of Action

Primary Mechanism: Non-Selective Enzyme Inhibition

The action of Ibuprofeno GP is the non-selective, reversible inhibition of the Cyclooxygenase ( COX-1 and COX-2) enzymes. This molecular interaction blocks the initial step in the Arachidonic Acid Cascade, thereby suppressing the production of key prostanoid mediators, specifically PGE2. This process involves the direct targeting of these enzymes responsible for generating specific regulatory signals within the body.

Pathway Modulation and Physiological Consequences

The resulting decrease in PGE2 concentration leads to the modulation of both nociceptive and thermoregulatory pathways. Peripherally, the reduced mediators decrease the sensitization of nociceptors (pain-sensing nerve endings), altering their response to stimuli. Centrally, the suppression of PGE2 within the hypothalamus resets the body's elevated temperature set-point.

Mechanistic Constraint

The non-selective nature of the inhibition means the drug affects both the inducible COX-2 and the constitutive COX-1 isoforms. This unavoidable COX-1 action restricts the synthesis of prostaglandins involved in maintaining gastric mucosal integrity and regulating renal blood flow. This constraint is inherent to the drug's core mechanism.

Dosage and Administration Information

How to Use Ibuprofeno GP: Administration Guidelines

This section outlines the instructions for using Ibuprofeno GP, detailing routes, dosing, and administration conditions.

Administration Scope

Feature	Instruction
Route of Administration	Primarily Oral (tablets, capsules, suspension). An Intravenous (IV) injection form also exists, typically for use in healthcare settings.
Standard Dosing Schedule	Dosing depends on the specific formulation and condition. Oral doses for adults typically range from 200 mg to 800 mg per dose. The maximum daily dose for over-the-counter (OTC) use is 1200 mg; for prescription use, it may be up to 3200 mg.
Frequency and Timing	Generally taken every 4 to 6 hours as needed. The minimum interval between doses must be respected.
Administration Conditions	Oral forms may be taken with food or milk to help reduce gastric irritation. Liquid suspensions must be shaken well before measuring the dose with the provided device.
Special Procedural Conditions	Certain formulations, such as extended-release tablets, must be swallowed whole and must not be crushed, split, or chewed. Use the lowest effective dosage for the shortest duration of time necessary.

Population-Specific Rules

Population	Instruction
Pediatric	Dosing for children is typically calculated based on body weight (mg/kg). Use in infants under 6 months is not established and requires strict medical oversight.
Geriatric	Dosage adjustments and close monitoring are often necessary due to a higher likelihood of age-related reduced kidney function.

Course Duration

For non-prescription use, do not take Ibuprofeno GP for more than 10 days for pain relief or 3 days for fever without consulting a healthcare provider.

Recent Clinical Evidence

Research evidence / Overview of studies for Ibuprofeno GP

Evidence for Symptomatic Relief of Acute Pain and Fever

Research on Ibuprofen has utilized numerous Randomized Controlled Trials (RCTs) and comprehensive meta-analyses to explore how symptoms change over time, and how pain and elevated body temperature were measured in trials. These studies were applied in research examining patient-reported experiences of pain, and outcomes related to systemic or functional imbalance, such as fever. In these research scenarios, studies monitored the change in pain intensity and tracked the reduction in body temperature from the starting measurement.

Studies report how symptoms evolved in the observed populations; measured changes in both pain and temperature were tracked compared to control groups. Findings describe patterns observed in the studies where the duration of monitored effect typically lasted for several hours post-administration. Despite the breadth of short-term data, long-term outcomes are not fully established regarding continuous administration in research contexts. Furthermore, data for certain health status groups remain limited; most fever research focuses heavily on children, meaning limited information is available from recent large-scale comparative trials focused exclusively on the fever response in adult populations.

Evidence for Managing Cyclical Pain (Dysmenorrhea)

Ibuprofen was also studied for conditions characterized by fluctuating or episodic manifestations, specifically the cyclical pain associated with primary dysmenorrhea (menstrual cramps). Research explored short-term symptom changes using both RCTs and network meta-analyses that included other non-prescription pain treatments. These studies examined symptom intensity or variability and outcomes capturing phases of heightened symptom activity.

Studies report how symptoms evolved in the observed populations, where findings describe patterns observed in the studies that were different from the patterns reported by control groups. Outcomes linked to inflammatory or irritative states were also monitored, where research highlights changes measured during the study period, such as a reduction in certain inflammatory mediators.

Evidence for Chronic Inflammatory Pain

For conditions involving periods of heightened symptoms, such as arthritis (including osteoarthritis and rheumatoid arthritis), Ibuprofen was evaluated in long-term Randomized Controlled Trials and extensive observational cohort studies. The research examined outcomes reflecting daily functioning or activity level, such as physical function scales and joint stiffness, and outcomes monitoring physiological strain or stress. Studies explored these symptoms in adult and older adult populations with chronic conditions.

What is Still Uncertain About the Research Base

While research provides context to understanding symptom patterns, there are recognized limitations. Long-term outcomes are not fully established for continuous use, particularly concerning chronic inflammatory pain, as trial follow-up durations were short in many controlled studies. Observational evidence has also led to research exploring a potential association between anti-inflammatory usage and long-term symptom persistence in certain pain conditions. Research highlights what is known—and what is still uncertain—about the drug's evidence landscape.

Key Studies & References National Institute for Health and Care Excellence (NICE) Guideline: Osteoarthritis: care and management

Frequently Asked Questions (FAQ)

Common questions about Ibuprofeno GP (FAQ)

Q: What does the acronym 'NSAID' mean when referring to Ibuprofeno GP?

A: NSAID is the acronym for Nonsteroidal Anti-inflammatory Drug, which is the pharmacological class of Ibuprofeno GP. This classification describes the medicine's three primary actions, which are to relieve pain (analgesic), reduce fever (antipyretic), and reduce inflammation (anti-inflammatory).

Q: How quickly should one typically expect Ibuprofeno GP to begin working?

A: Official prescribing information indicates that the onset of pain relief is typically reported to be within 30 minutes after oral administration. This information helps describe the expected performance of the medicine as detailed in regulatory studies.

Q: What is the official description of using Ibuprofeno GP during the first two trimesters of pregnancy?

A: Regulatory documents state that during the first and second trimesters of pregnancy, the medicine is only used if the benefit justifies the risk, as determined by a healthcare provider. Use is typically restricted to the lowest effective dose for the shortest duration necessary, reflecting official caution during this period.

Q: What types of food or beverages are generally mentioned as potentially interacting with Ibuprofeno GP?

A: Regulatory information does not typically list specific foods or non-alcoholic beverages that are known to interact with Ibuprofeno GP. However, warnings are consistently provided regarding the use of alcohol. Combining this medicine with alcohol is associated with an increased risk of serious side effects, such as stomach bleeding.

Q: Can Ibuprofeno GP potentially affect liver enzyme levels?

A: Yes, official drug labels describe a potential for Ibuprofeno GP to affect the liver. In rare instances, use has been associated with temporary elevations of liver enzymes. In very severe cases, liver toxicity has been reported, which is why contraindications exist for people with severe liver failure.

Q: Is drowsiness or dizziness listed as a possible adverse reaction to Ibuprofeno GP?

A: According to regulatory reports, certain nervous system effects are possible with Ibuprofeno GP. Official adverse reaction information lists both dizziness and drowsiness (also known as somnolence) as reactions that may occur in some individuals.

Q: Is Ibuprofeno GP classified as a narcotic or a drug with dependence potential?

A: Ibuprofeno GP is a nonsteroidal anti-inflammatory drug (NSAID) and is not classified by regulatory bodies as a narcotic substance. Furthermore, official documents do not describe this medicine as having a known potential for physical dependence or abuse.

Q: Does Ibuprofeno GP have a specific regulatory boxed warning?

A: Yes, the official prescribing information issued by the FDA includes a Boxed Warning. This is a required statement used to highlight the risks of serious cardiovascular thrombotic events, such as heart attack and stroke. It also emphasizes the risk of serious gastrointestinal adverse events, including bleeding and ulceration.

Q: What is the typical shelf life of Ibuprofeno GP as indicated on the packaging?

A: The shelf life is determined by stability testing and results in the expiration date printed on the packaging. This date indicates the time frame during which the product remains potent and safe when stored under recommended conditions. The stability data often results in a typical shelf life of two to three years from the date of manufacture.

Q: What official guidance exists regarding the use of Ibuprofeno GP by patients with asthma?

A: Regulatory warnings state that Ibuprofeno GP is generally contraindicated for individuals who have a history of aspirin-sensitive asthma. This is because its use is associated with the risk of triggering severe reactions, such as bronchospasm (sudden airway narrowing), in this sensitive population.

Q: Does Ibuprofeno GP interact with common non-prescription pain relievers like acetaminophen?

A: Official drug interaction documents do not list an adverse interaction between Ibuprofeno GP and acetaminophen (which is also known as paracetamol). However, regulatory documents strongly caution against using Ibuprofeno GP at the same time as any other NSAID due to the significantly increased risk of side effects.

Q: What information is available about the use of Ibuprofeno GP while breastfeeding?

A: Studies and official information indicate that Ibuprofeno GP is secreted into breast milk, but usually in very low concentrations. The amounts present are generally considered unlikely to pose a significant risk to a breastfed infant when the medicine is used at standard doses and for short treatment durations.

Q: Are there official descriptions of what happens if a dose of Ibuprofeno GP is forgotten?

A: Official administration instructions emphasize the importance of maintaining the minimum time interval between doses to avoid excessive intake. While specific forgotten dose instructions are not always provided, regulatory guidance generally advises against taking a double dose to compensate for a missed one.

Q: What does the regulatory classification of Ibuprofeno GP indicate about its safety profile?

A: The official regulatory classification designates Ibuprofeno GP as a non-narcotic analgesic. Its safety profile is comprehensively described by the official contraindications, which define who absolutely cannot use the drug. Furthermore, its regulatory status includes the explicit Boxed Warning highlighting risks like serious cardiovascular and gastrointestinal events.

Q: What is the official description of how Ibuprofeno GP is metabolized and eliminated by the body?

A: Official pharmacokinetics information details how the body processes Ibuprofeno GP. The medicine is rapidly absorbed after administration and is then extensively metabolized (broken down) in the liver. The original drug compound and its inactive components are then primarily eliminated from the body via the urine within about 24 hours.

Q: Are there specific warnings about sun exposure or photosensitivity while taking Ibuprofeno GP?

A: Yes, official adverse reaction information lists the possibility of photosensitivity reactions as an uncommon or rare side effect of Ibuprofeno GP. This means that some people may experience an increased sensitivity to sunlight or artificial UV light while using the medicine.

Q: What research themes cover the use of Ibuprofeno GP for symptoms of the common cold or flu?

A: Ibuprofeno GP is officially indicated for the symptomatic relief of pain and fever, which are the two most common symptoms associated with the cold and flu. Research evidence themes, therefore, cover the measured reduction in elevated body temperature and the change in acute pain intensity.

Q: What is the general guidance on stopping Ibuprofeno GP before scheduled surgical procedures?

A: Official warnings related to Ibuprofeno GP's effect on bleeding state that Ibuprofeno GP is generally recommended to be discontinued before scheduled elective surgery. This guidance is based on the potential risk of bleeding complications during the procedure.

Q: Are there official descriptions of the use of Ibuprofeno GP for migraine headaches?

A: Official indications for Ibuprofeno GP include the symptomatic treatment of general headache. Furthermore, official product documents for certain specific formulations also list the acute treatment of migraine headache as an approved use.

Q: What is the description of an overdose of Ibuprofeno GP and what general steps are recommended?

A: Official documents describe that signs of a substantial overdose can include effects such as nausea, vomiting, headache, ringing in the ears (tinnitus), and extreme tiredness (lethargy). In the event that an overdose is known or suspected, the consistent and official advice is to ensure emergency medical assistance is contacted immediately.

Q: Can Ibuprofeno GP cause a 'rebound headache' if used too often, according to official warnings?

A: Yes, official warnings exist about using this medicine too frequently for headache relief. Using Ibuprofeno GP for prolonged periods may lead to the symptoms of medication overuse headache, which is sometimes referred to by patients as a 'rebound headache'.

Q: Is anxiety or nervousness listed as a possible adverse effect of Ibuprofeno GP?

A: Official reports of adverse effects include psychiatric disorders within the list of possible reactions. These documented effects can include feelings of anxiety and nervousness, which are listed as rare or infrequent reactions to the medicine.

Q: What is the official designation for the inactive ingredients in Ibuprofeno GP tablets?

A: Regulatory documents require a complete listing of all components of the tablet, including the inactive ingredients, or excipients. These compounds are present to serve necessary functions, such as providing the tablet's required structure, color, or stability, but they do not contribute to the medicine's therapeutic effect.

Q: What information is provided about the appearance of the Ibuprofeno GP tablet?

A: Official descriptions are provided in regulatory documents that define the physical appearance of the Ibuprofeno GP dosage form. This information typically includes the tablet's shape, size, and color, along with any identifying markings or imprints used for product recognition.

How should Ibuprofeno GP be stored and disposed of?

Storage and Disposal Instructions for Ibuprofeno GP

Ibuprofen must be stored according to regulatory requirements to ensure its stability and safety. The product requires storage at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), and must be protected from excessive heat, with temperatures above 40 C strictly avoided. Liquid formulations should not be frozen.

Handling and Safety

The medicine must be stored out of the sight and reach of children and kept in its tightly closed original container to protect it from moisture. Do not use the product past its stated expiration date.

Disposal

Unused or expired Ibuprofen should be discarded using authorized drug take-back programs. If this option is unavailable, the product may be placed in the household trash after being mixed with an undesirable substance, such as dirt or used coffee grounds, and sealed in a container. Disposal must be in accordance with local requirements.

Ibuprofeno GP